Spanish Scientists Eradicate Pancreatic Tumors in Mice Using Triple-Drug Therapy

Researchers at Spain’s National Cancer Research Centre (CNIO) have reported a major preclinical advance against pancreatic cancer after successfully eliminating aggressive tumors in laboratory mice using a novel three-drug combination therapy.

The study, led by scientist Dr. Mariano Barbacid, demonstrated that the experimental treatment could completely regress tumors and prevent resistance, addressing one of the biggest hurdles in pancreatic cancer therapy.

Pancreatic ductal adenocarcinoma — the most common and lethal form of pancreatic cancer — has historically shown strong resistance to single-agent treatments, resulting in extremely low five-year survival rates worldwide.

The CNIO team designed a triple-drug regimen that targets multiple signaling pathways the tumor relies on, overcoming mechanisms that typically allow it to evade treatment.

In multiple mouse models, the therapy led to total tumor disappearance with minimal side effects and no evidence of relapse, suggesting that blocking the cancer’s “escape routes” holds promise for more durable responses.

Despite the striking results in animals, experts emphasise that the findings are preclinical and have not yet been tested in humans. Extensive future studies will be needed to assess the safety, optimal dosing, and effectiveness of this approach in patients.

Scientists nevertheless describe the findings as an important proof of concept that could reshape research and treatment strategies for a cancer long considered among the hardest to treat.